Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
Japan’s key reimbursement policy panel on July 5 held its first industry hearing towards the FY2024 drug pricing reform. Groups of research-driven drug makers stressed the need for new mechanisms to properly evaluate innovative new medicines and ensure their price…
To read the full story
Related Article
- Amid High Turnover Rate, JPWA Presses for New System to Support Drug Prices
July 7, 2023
- Industry Stresses Stronger Price Support Rule to Ensure Stable Supplies
July 7, 2023
- JPMA Pushes Simple Price Maintenance for Innovative Meds; PhRMA, EFPIA in Sync
July 6, 2023
- Discuss Drug Price Revision System That Doesn’t Cause Yakkasa: FPMAJ Chair
July 6, 2023
- Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
- 5 FPMAJ-Affiliated Bodies Petition Expanded Coverage, Eased Criteria for Essential Drug Rule
July 6, 2023
REGULATORY
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
- Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
- Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…